We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Sunday
May 04
10:30 - 11:30
Mahler
Transformative combined modality treatment strategies
Anthony Chalmers, United Kingdom;
Dorota Gabrys, Poland
Proffered Papers are presented in one of the sessions scheduled in the main session halls. Each author will present orally for 7 minutes, followed by 3 minutes for discussion. Sessions will be recorded and available on-demand.
Proffered Papers
Interdisciplinary
Lung / Urology
10:30 - 10:40
Osimertinib after chemoradiotherapy in unresectable stage III EGFRm NSCLC: chemoradiotherapy regimens and radiation pneumonitis in LAURA (NCT03521154)
Terufumi Kato, Japan
E25-2645
10:40 - 10:50
SBRT with or without Darolutamide for OligoRecurrent prostate cancer (DART): 6-month quality of life from a randomized phase II trial
Piet Ost, Belgium
E25-3556
10:50 - 11:00
Safety of metastasis-directed SBRT in oligometastatic patients treated with and without concomitant systemic therapy: an interim analysis of OligoCare
Ciro Franzese, Italy
E25-3724
11:00 - 11:10
Exploring the Systemic Immunological Impact of Stereotactic Radiotherapy: A Flow Cytometry-based Investigation (iDOSE study)
Nora Purcell, Netherlands Antilles
E25-3645
11:10 - 11:20
Combining SBRT and durvalumab in hormone-sensitive prostate cancer with oligorecurrent metastases: a randomized phase II trial (POSTCARD GETUG P13)
Stephane Supiot, France
E25-2467
11:20 - 11:30
A clinical and biomarker-based model to predict futile chemoradiotherapy (CRT) in patients with stage III non-small cell lung cancer (NSCLC)
Dirk De Ruysscher, The Netherlands
E25-2556